What is IBS-D Phase III Ibodutant IRIS-3 Study?

Category: Others

false

The IBS-D IRIS-3 study is a clinical trial examining the efficacy and safety of oral ibodutant for women experiencing irritable bowel syndrome with diarrhea.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
1
None
0

Commonly reported side effects and conditions associated with IBS-D Phase III Ibodutant IRIS-3 Study

Side effect Patients
Hair loss 1

Why patients stopped taking IBS-D Phase III Ibodutant IRIS-3 Study

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using IBS-D Phase III Ibodutant IRIS-3 Study

Duration

Stopped using IBS-D Phase III Ibodutant IRIS-3 Study

Duration Patients
1 - 6 months 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for IBS-D Phase III Ibodutant IRIS-3 Study.